Brokerages Set Kenvue Inc. (NYSE:KVUE) Price Target at $22.64

Kenvue Inc. (NYSE:KVUE) has received a consensus recommendation of “Hold” from the twelve research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $22.64.

A number of equities research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft upped their target price on Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Bank of America upped their target price on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. UBS Group upped their target price on Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Jefferies Financial Group assumed coverage on Kenvue in a research report on Tuesday, September 24th. They set a “buy” rating and a $27.00 target price for the company. Finally, Piper Sandler upped their target price on Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research report on Monday, September 23rd.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Riverview Trust Co acquired a new position in shares of Kenvue in the third quarter valued at $30,000. Ashton Thomas Securities LLC acquired a new position in shares of Kenvue in the third quarter valued at $35,000. Studio Investment Management LLC raised its stake in Kenvue by 52.1% during the second quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock worth $45,000 after acquiring an additional 845 shares in the last quarter. Deseret Mutual Benefit Administrators raised its stake in Kenvue by 49.7% during the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock worth $45,000 after acquiring an additional 651 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new position in Kenvue during the second quarter worth $61,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Trading Down 1.3 %

NYSE:KVUE opened at $23.18 on Friday. The stock’s 50 day moving average price is $22.97 and its 200 day moving average price is $21.05. Kenvue has a 52 week low of $17.67 and a 52 week high of $24.46. The company has a market capitalization of $44.44 billion, a P/E ratio of 42.15, a P/E/G ratio of 2.20 and a beta of 1.37. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The firm had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same quarter in the prior year, the company posted $0.31 earnings per share. The firm’s revenue was down .4% on a year-over-year basis. On average, research analysts forecast that Kenvue will post 1.07 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th were paid a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.54%. Kenvue’s payout ratio is 149.09%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.